{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:37:50Z","timestamp":1769848670225,"version":"3.49.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T00:00:00Z","timestamp":1682294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Primary cutaneous lymphoma (PCL)\u00a0is a cutaneous non-Hodgkin\u2019s lymphoma that originates in the skin and lacks extracutaneous spread upon initial diagnosis. The clinical management of secondary cutaneous lymphomas is different from that of PCLs, and earlier detection is associated with better prognosis. Accurate staging is necessary to determine the extent of disease and to choose the appropriate treatment. The aim of this review is to investigate the current and potential roles of <jats:sup>18<\/jats:sup>F- fluorodeoxyglucose positron emission tomography\u2013computed tomography (<jats:sup>18<\/jats:sup>F-FDG PET\/CT) in the diagnosis, staging, and monitoring of PCLs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A focused review of the scientific literature was performed using inclusion criteria to filter results pertaining to human clinical studies performed between 2015 and 2021 that analyzed cutaneous PCL lesions on <jats:sup>18<\/jats:sup>F PET\/CT imaging.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results &amp; Conclusion<\/jats:title>\n                <jats:p>A review of 9 clinical studies published after 2015 concluded that <jats:sup>18<\/jats:sup>F-FDG PET\/CT is highly sensitive and specific for aggressive PCLs and proved valuable for identifying extracutaneous disease. These studies found <jats:sup>18<\/jats:sup>F-FDG PET\/CT highly useful for guiding lymph node biopsy and that imaging results influenced therapeutic decision in many cases. These studies also predominantly concluded that <jats:sup>18<\/jats:sup>F-FDG PET\/CT is more sensitive than computed tomography (CT) alone for detection of subcutaneous PCL lesions. Routine revision of nonattenuation-corrected (NAC) PET images may improve the sensitivity of <jats:sup>18<\/jats:sup>F-FDG PET\/CT for detection of indolent cutaneous lesions and may expand the potential uses of <jats:sup>18<\/jats:sup>F-FDG PET\/CT in the clinic<jats:italic>.<\/jats:italic> Furthermore, calculating a global disease score from <jats:sup>18<\/jats:sup>F-FDG PET\/CT at every follow-up visit may simplify assessment of disease progression in the early clinical stages, as well as predict the prognosis of disease in patients with PCL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12149-023-01830-3","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T21:02:00Z","timestamp":1682370120000},"page":"328-348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of 18F-FDG PET\/CT in primary cutaneous lymphoma: an educational review"],"prefix":"10.1007","volume":"37","author":[{"given":"Elysia O.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir A.","family":"Amanullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Sang Uk","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3300-7420","authenticated-orcid":false,"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,24]]},"reference":[{"issue":"suppl 4","key":"1830_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Committee EG. Primary cutaneous lymphomas ESMO clinical Practice Guidelines for diagnosis treatment and follow-up. Ann Oncol. 2018;29(suppl 4):30\u201340.","journal-title":"Ann Oncol"},{"issue":"16","key":"1830_CR2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","volume":"133","author":"R Willemze","year":"2019","unstructured":"Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703\u201314.","journal-title":"Blood"},{"issue":"10","key":"1830_CR3","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","volume":"105","author":"R Willemze","year":"2005","unstructured":"Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768\u201385.","journal-title":"Blood"},{"issue":"20","key":"1830_CR4","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390.","journal-title":"Blood"},{"issue":"1","key":"1830_CR5","first-page":"7","volume":"12","author":"CD Klemke","year":"2014","unstructured":"Klemke CD. Cutaneous lymphomas. J Dtsch Dermatol Ges. 2014;12(1):7\u20132.","journal-title":"J Dtsch Dermatol Ges"},{"key":"1830_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.650822","volume":"11","author":"M Jiang","year":"2021","unstructured":"Jiang M, Zhao L, Zheng J, Zhang J, Chen P, Zhou W. Report of eleven patients of subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic features, (18)F-FDG PET\/CT findings and outcome. Front Oncol. 2021;11: 650822.","journal-title":"Front Oncol"},{"issue":"4","key":"1830_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.det.2015.06.001","volume":"33","author":"EA Olsen","year":"2015","unstructured":"Olsen EA. Evaluation, diagnosis, and staging of cutaneous lymphoma. Dermatol Clin. 2015;33(4):643\u201354.","journal-title":"Dermatol Clin"},{"issue":"5","key":"1830_CR8","doi-asserted-by":"publisher","first-page":"368","DOI":"10.5114\/pdia.2015.54749","volume":"32","author":"M Sokolowska-Wojdylo","year":"2015","unstructured":"Sokolowska-Wojdylo M, Olek-Hrab K, Ruckemann-Dziurdzinska K. Primary cutaneous lymphomas: diagnosis and treatment. Postepy Dermatol Alergol. 2015;32(5):368\u201383.","journal-title":"Postepy Dermatol Alergol"},{"issue":"6","key":"1830_CR9","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","volume":"110","author":"E Olsen","year":"2007","unstructured":"Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC). Blood. 2007;110(6):1713\u201322.","journal-title":"Blood"},{"issue":"2","key":"1830_CR10","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"YH Kim","year":"2007","unstructured":"Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the international society for cutaneous lymphomas (ISCL) and the cutaneous lymphoma task force of the European organization of research and treatment of cancer (EORTC). Blood. 2007;110(2):479\u201384.","journal-title":"Blood"},{"issue":"18","key":"1830_CR11","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous lymphomas, the united states cutaneous lymphoma consortium, and the cutaneous lymphoma Task Force of the European organisation for research and treatment of Cancer. J Clin Oncol. 2011;29(18):2598\u2013607.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1830_CR12","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1080\/0284186X.2021.1956689","volume":"60","author":"M Olszewska-Szopa","year":"2021","unstructured":"Olszewska-Szopa M, Sobas M, Laribi K, Bao Perez L, Drozd-Sokolowska J, Subocz E, et al. Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature. Acta Oncol. 2021;60(10):1361\u20138.","journal-title":"Acta Oncol"},{"issue":"10","key":"1830_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1093\/jjco\/hyz111","volume":"49","author":"W Munakata","year":"2019","unstructured":"Munakata W, Terauchi T, Maruyama D, Nagai H. Revised staging system for malignant lymphoma based on the Lugano classification. Jpn J Clin Oncol. 2019;49(10):895\u2013900.","journal-title":"Jpn J Clin Oncol"},{"issue":"27","key":"1830_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059\u201368.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1830_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"P Solal-Celigny","year":"1993","unstructured":"Solal-Celigny P. International Non-hodgkin\u2019s lymphoma prognostic factors p a predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med"},{"issue":"5","key":"1830_CR16","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258\u201365.","journal-title":"Blood"},{"issue":"2","key":"1830_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558\u201365.","journal-title":"Blood"},{"issue":"7","key":"1830_CR18","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.ejrad.2015.03.028","volume":"84","author":"S Dan","year":"2015","unstructured":"Dan S, Qiang G, Shu-Xia W, Chang-Hong L. Preliminary discussion on the value of (18)F-FDG PET\/CT in the diagnosis and early staging of non-mycosis fungoides\/Sezary\u2019s syndrome cutaneous malignant lymphomas. Eur J Radiol. 2015;84(7):1293\u20138.","journal-title":"Eur J Radiol"},{"issue":"4","key":"1830_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.clml.2019.09.611","volume":"20","author":"T Davidson","year":"2020","unstructured":"Davidson T, Avigdor A, Oksman Y, Nissan E, Zlotnick M, Chikman B, et al. PET\/CT in disease detection and Follow-up of Subcutaneous involvement in marginal zone lymphoma. Clin Lymphoma Myeloma Leuk. 2020;20(4):252\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"1830_CR20","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MNM.0000000000000463","volume":"37","author":"C Liu","year":"2016","unstructured":"Liu C, Zhang Y, Zhang Y, Wang M, Liu R, Liu X, et al. Diagnostic value of 18F-FDG PET\/CT for cutaneous extranodal natural killer\/T-cell lymphoma, nasal type. Nucl Med Commun. 2016;37(5):446\u201352.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"1830_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1684\/ejd.2017.3083","volume":"27","author":"C Ram-Wolff","year":"2017","unstructured":"Ram-Wolff C, Vercellino L, Brice P, La Selva R, Bagot M. (18)F-fluorodeoxyglucose-positron emission tomography is more sensitive than computed tomography in initial staging of patients with an anaplastic T-cell lymphoma first presenting in the skin. Eur J Dermatol. 2017;27(5):496\u2013504.","journal-title":"Eur J Dermatol"},{"issue":"3","key":"1830_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4103\/0972-3919.158527","volume":"30","author":"E Alanteri","year":"2015","unstructured":"Alanteri E, Usmani S, Marafi F, Esmail A, Ali A, Elhagracy RS, et al. The role of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with mycosis fungoides. Indian J Nucl Med. 2015;30(3):199\u2013203.","journal-title":"Indian J Nucl Med"},{"issue":"1095","key":"1830_CR23","doi-asserted-by":"publisher","first-page":"20180904","DOI":"10.1259\/bjr.20180904","volume":"92","author":"A Mandava","year":"2019","unstructured":"Mandava A, Koppula V, Wortsman X, Catalano O, Alfageme F. The clinical value of imaging in primary cutaneous lymphomas: role of high resolution ultrasound and PET-CT. Br J Radiol. 2019;92(1095):20180904.","journal-title":"Br J Radiol"},{"issue":"9","key":"1830_CR24","first-page":"580","volume":"21","author":"H Feuerman","year":"2019","unstructured":"Feuerman H, Snast I, Amitay-Laish I, Bairey O, Barzilai A, Feinmesser M, et al. The Utility of 18F-fluorodeoxyglucose positron-emission tomography\/computed tomography in cutaneous B-cell lymphoma. Isr Med Assoc J. 2019;21(9):580\u20134.","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"1830_CR25","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/MNM.0000000000000614","volume":"38","author":"L Qiu","year":"2017","unstructured":"Qiu L, Tu G, Li J, Chen Y. The role of 18F-FDG PET and PET\/CT in the evaluation of primary cutaneous lymphoma. Nucl Med Commun. 2017;38(2):106\u201316.","journal-title":"Nucl Med Commun"},{"issue":"2","key":"1830_CR26","first-page":"78","volume":"17","author":"N Spaccarelli","year":"2014","unstructured":"Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A. Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med. 2014;17(2):78\u201384.","journal-title":"Hell J Nucl Med"},{"issue":"1","key":"1830_CR27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/RLU.0000000000003962","volume":"47","author":"A Alavi","year":"2022","unstructured":"Alavi A, Saboury B, Nardo L, Zhang V, Wang M, Li H, et al. Potential and most relevant applications of total body PET\/CT imaging. Clin Nucl Med. 2022;47(1):43\u201355.","journal-title":"Clin Nucl Med"},{"issue":"5","key":"1830_CR28","first-page":"265","volume":"10","author":"E Kothekar","year":"2020","unstructured":"Kothekar E, Revheim ME, Borja AJ, Hancin EC, Detchou DK, Werner TJ, et al. Utility of FDG-PET\/CT in clinical psoriasis grading: the PET-PASI scoring system. Am J Nucl Med Mol Imaging. 2020;10(5):265\u201371.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"9","key":"1830_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/RLU.0000000000000851","volume":"40","author":"A Bakshi","year":"2015","unstructured":"Bakshi A, Gholami S, Alavi A, Gelfand JM, Takeshita J. Assessing cutaneous psoriasis activity using FDG-PET: nonattenuation corrected versus attenuation corrected PET images. Clin Nucl Med. 2015;40(9):727\u20139.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1830_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.4103\/0972-3919.183619","volume":"31","author":"P Chandra","year":"2016","unstructured":"Chandra P, Agrawal A, Purandare N, Shah S, Rangarajan V. Importance of assessing nonattenuation-corrected positron emission tomography images in treatment response evaluation of primary cutaneous lymphoma. Indian J Nucl Med. 2016;31(3):244\u20135.","journal-title":"Indian J Nucl Med"},{"issue":"11","key":"1830_CR31","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1007\/s00259-014-2826-3","volume":"41","author":"S Basu","year":"2014","unstructured":"Basu S, Zaidi H, Salavati A, Hess S, Carlsen PF, Alavi A. FDG PET\/CT methodology for evaluation of treatment response in lymphoma: from \u201cgraded visual analysis\u201d and \u201csemiquantitative SUVmax\u201d to global disease burden assessment. Eur J Nucl Med Mol Imaging. 2014;41(11):2158\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1830_CR32","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1007\/s00259-019-04383-8","volume":"46","author":"PF Hoilund-Carlsen","year":"2019","unstructured":"Hoilund-Carlsen PF, Edenbrandt L, Alavi A. Global disease score (GDS) is the name of the game! Eur J Nucl Med Mol Imaging. 2019;46(9):1768\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"1830_CR33","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3109\/10428194.2010.529208","volume":"51","author":"M Meignan","year":"2010","unstructured":"Meignan M, Gallamini A, Haioun C, Polliack A. Report on the second international workshop on interim positron emission tomography in lymphoma held in menton, France, 8\u20139 April 2010. Leuk Lymphoma. 2010;51(12):2171\u201380.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"1830_CR34","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257\u201360.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"1830_CR35","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","volume":"28","author":"A Younes","year":"2017","unstructured":"Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International working group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28(7):1436\u201347.","journal-title":"Ann Oncol"},{"issue":"1","key":"1830_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cpet.2020.09.013","volume":"16","author":"PF Hoilund-Carlsen","year":"2021","unstructured":"Hoilund-Carlsen PF, Piri R, Gerke O, Edenbrandt L, Alavi A. Assessment of total-body atherosclerosis by PET\/computed tomography. PET Clin. 2021;16(1):119\u201328.","journal-title":"PET Clin"},{"issue":"1","key":"1830_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/00365521.2017.1390600","volume":"53","author":"K Palatka","year":"2018","unstructured":"Palatka K, Kacska S, Lovas S, Garai I, Varga J, Galuska L. The potential role of FDG PET-CT in the characterization of the activity of Crohn\u2019s disease, staging follow-up and prognosis estimation: a pilot study. Scand J Gastroenterol. 2018;53(1):24\u201330.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"1830_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/RLU.0000000000004135","volume":"47","author":"C Bezzi","year":"2022","unstructured":"Bezzi C, Monaco L, Ghezzo S, Mathoux G, Bergamini A, Zambella E, et al. 18F-FDG PET\/CT may predict tumor type and risk score in gestational trophoblastic disease. Clin Nucl Med. 2022;47(6):525\u201331.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"1830_CR39","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1007\/s12350-017-0977-x","volume":"25","author":"A Alavi","year":"2018","unstructured":"Alavi A, Werner TJ, Hoilund-Carlsen PF. What can be and what cannot be accomplished with PET to detect and characterize atherosclerotic plaques. J Nucl Cardiol. 2018;25(6):2012\u20135.","journal-title":"J Nucl Cardiol"},{"issue":"8","key":"1830_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1097\/RLU.0000000000001695","volume":"42","author":"A Alavi","year":"2017","unstructured":"Alavi A, Werner TJ, Hoilund-Carlsen PF. What can be and what cannot Be accomplished with PET: rectifying ongoing misconceptions. Clin Nucl Med. 2017;42(8):603\u20135.","journal-title":"Clin Nucl Med"},{"issue":"15","key":"1830_CR41","doi-asserted-by":"publisher","first-page":"5509","DOI":"10.1002\/cam4.3226","volume":"9","author":"A Kitadate","year":"2020","unstructured":"Kitadate A, Narita K, Fukumoto K, Terao T, Tsushima T, Kobayashi H, et al. Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma. Cancer Med. 2020;9(15):5509\u201318.","journal-title":"Cancer Med"},{"issue":"2","key":"1830_CR42","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00259-017-3843-9","volume":"45","author":"H Grut","year":"2018","unstructured":"Grut H, Dueland S, Line PD, Revheim ME. The prognostic value of (18)F-FDG PET\/CT prior to liver transplantation for nonresectable colorectal liver metastases. Eur J Nucl Med Mol Imaging. 2018;45(2):218\u201325.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1830_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698744","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Liu X, Wang W, Huo L, Pan Q, Ren X, et al. The role of the metabolic parameters of (18)F-FDG PET\/CT in patients with locally advanced cervical cancer. Front Oncol. 2021;11: 698744.","journal-title":"Front Oncol"},{"issue":"4","key":"1830_CR44","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cpet.2014.07.006","volume":"9","author":"S Basu","year":"2014","unstructured":"Basu S, Hess S, Nielsen Braad PE, Olsen BB, Inglev S, Hoilund-Carlsen PF. The basic principles of FDG-PET\/CT imaging. PET Clin. 2014;9(4):355\u201370.","journal-title":"PET Clin"},{"issue":"3","key":"1830_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.cpet.2019.03.003","volume":"14","author":"WY Raynor","year":"2019","unstructured":"Raynor WY, Zadeh MZ, Kothekar E, Yellanki DP, Alavi A. Evolving role of PET-based novel quantitative techniques in the management of hematological malignancies. PET Clin. 2019;14(3):331\u201340.","journal-title":"PET Clin"},{"issue":"2","key":"1830_CR46","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1830_CR47","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.cpet.2014.09.004","volume":"10","author":"S Houshmand","year":"2015","unstructured":"Houshmand S, Salavati A, Hess S, Werner TJ, Alavi A, Zaidi H. An update on novel quantitative techniques in the context of evolving whole-body PET imaging. PET Clin. 2015;10(1):45\u201358.","journal-title":"PET Clin"},{"issue":"1","key":"1830_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13550-020-00698-y","volume":"10","author":"C Jiang","year":"2020","unstructured":"Jiang C, Teng Y, Chen J, Wang Z, Zhou Z, Ding C, et al. Baseline total metabolic tumor volume combined with international peripheral T-cell lymphoma project may improve prognostic stratification for patients with peripheral T-cell lymphoma (PTCL). EJNMMI Res. 2020;10(1):110.","journal-title":"EJNMMI Res"},{"issue":"1","key":"1830_CR49","first-page":"5","volume":"12","author":"M Houseni","year":"2009","unstructured":"Houseni M, Chamroonrat W, Basu S, Bural G, Mavi A, Kumar R, et al. Usefulness of non attenuation corrected 18F-FDG-PET images for optimal assessment of disease activity in patients with lymphoma. Hell J Nucl Med. 2009;12(1):5\u20139.","journal-title":"Hell J Nucl Med"},{"issue":"12","key":"1830_CR50","first-page":"2021","volume":"40","author":"C Bleckmann","year":"1999","unstructured":"Bleckmann C, Dose J, Bohuslavizki KH, Buchert R, Klutmann S, Mester J, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer. J Nucl Med. 1999;40(12):2021\u20134.","journal-title":"J Nucl Med"},{"issue":"9","key":"1830_CR51","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","volume":"147","author":"NN Mehta","year":"2011","unstructured":"Mehta NN, Yu Y, Saboury B, Foroughi N, Krishnamoorthy P, Raper A, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): a pilot study. Arch Dermatol. 2011;147(9):1031\u20139.","journal-title":"Arch Dermatol"},{"issue":"1","key":"1830_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/RLU.0b013e3181feedff","volume":"36","author":"C Bruna-Muraille","year":"2011","unstructured":"Bruna-Muraille C, Pochart JM, Papathanassiou D, Guedec-Ghelfi R, Cuif-Job A, Liehn JC. Incidental finding of F-18 FDG skin uptake in a patient with psoriasis during the evaluation of a recurrent papillary thyroid carcinoma. Clin Nucl Med. 2011;36(1):34\u20135.","journal-title":"Clin Nucl Med"},{"issue":"6","key":"1830_CR53","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2967\/jnumed.120.250597","volume":"62","author":"BA Spencer","year":"2021","unstructured":"Spencer BA, Berg E, Schmall JP, Omidvari N, Leung EK, Abdelhafez YG, et al. Performance Evaluation of the uEXPLORER Total-Body PET\/CT scanner based on NEMA NU 2\u20132018 with additional tests to characterize PET scanners with a long axial field of view. J Nucl Med. 2021;62(6):861\u201370.","journal-title":"J Nucl Med"},{"issue":"5","key":"1830_CR54","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1073\/pnas.1917379117","volume":"117","author":"X Zhang","year":"2020","unstructured":"Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020;117(5):2265\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1830_CR55","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S0969-8051(97)00226-6","volume":"25","author":"EK Pauwels","year":"1998","unstructured":"Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol. 1998;25(4):317\u201322.","journal-title":"Nucl Med Biol"},{"issue":"9","key":"1830_CR56","first-page":"1412","volume":"42","author":"H Zhuang","year":"2001","unstructured":"Zhuang H, Pourdehnad M, Lambright ES, Yamamoto AJ, Lanuti M, Li P, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42(9):1412\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1830_CR57","first-page":"9","volume":"53","author":"S Basu","year":"2009","unstructured":"Basu S, Kung J, Houseni M, Zhuang H, Tidmarsh GF, Alavi A. Temporal profile of fluorodeoxyglucose uptake in malignant lesions and normal organs over extended time periods in patients with lung carcinoma: implications for its utilization in assessing malignant lesions. Q J Nucl Med Mol Imaging. 2009;53(1):9\u201319.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"11","key":"1830_CR58","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2967\/jnumed.111.093716","volume":"46","author":"R Kumar","year":"2005","unstructured":"Kumar R, Loving VA, Chauhan A, Zhuang H, Mitchell S, Alavi A. Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med. 2005;46(11):1819\u201324.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-023-01830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-023-01830-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-023-01830-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T10:59:56Z","timestamp":1684407596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-023-01830-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,24]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1007\/s12149-023-01830-3","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,24]]},"assertion":[{"value":"18 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"An institutional consent form for all individual data included in this review was submitted and signed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}